Second-line CML drug evokes faster response, fewer side effects, pivotal study finds
Saturday, June 5, 2010 - 10:50
in Health & Medicine
CHICAGO – Dasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukemia (CML), provided patients with quicker, better responses as a first therapy than the...